Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

NCT01970371 is registered in ClinicalTrials.gov with Achaogen, Inc. as lead sponsor.

NCT NCT01970371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Lead sponsor
Achaogen, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 16, 2014
Completion date
September 15, 2016
Enrollment
69 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis (ap) due to cre, bloodstream infections (bsi) due to cre, complicated urinary tract infection (cuti) due to cre, hospital-acquired bacterial pneumonia (habp) due to cre, ventilator-associated bacterial pneumonia (vabp) due to cre